

INTRODUCTION

Wilson's disease (WD) is an inherited disease of toxic accumulation of Copper (Cu) mainly affecting the brain and liver^{1,2}. We describe a case of acute on chronic liver failure caused by WD while being stable on Zinc (Zn) maintenance therapy for 35 years after initial treatment with ammonium (NH₄) tetrathiomolybdate.

CASE PRESENTATION

- 58-year-old Caucasian male with WD presented to a local hospital with acute onset of jaundice and dark urine.
- He is a minimal alcohol drinker. He had no exposures to hepatotoxic agents and no prior evidence of liver fibrosis or decompensation.
- Diagnosed WD at age 18 with neurologic symptoms and was treated in a clinical trial with NH₄ tetrathiomolybdate at the time of diagnosis followed by Zn monotherapy.
- His Zn dosage was adjusted by his PCP based on blood level.

On admission:

- Vitals were stable
- Exam revealed jaundice, scleral icterus, and abdominal distension. No encephalopathy or asterixis was present
- Labs were notable for INR 2.4, ALP/AST/ALT 86/148/47 IU/L, Tbili 12.6 mg/dL, Cr 0.9 mg/dL, mildly elevated Cu, and normal ceruloplasmin.
- CT abdomen noted cirrhotic liver morphology




Figure 1. Trend of patient's total bilirubin, creatinine, and INR during hospitalization

HOSPITAL COURSE

- **DAY 1** – he was transferred to our hospital for an urgent liver transplant (LT) evaluation
- An extensive liver workup demonstrated negative for viral and autoimmune hepatitis, ethanol, acetaminophen, and salicylate overdose.
- His hospital course was complicated by rapidly progressive with active hemolysis and elevated total bilirubin (peaked at 60.1) and creatinine
- **DAY 2** – he was sent to ICU for dialysis and was listed for transplant as Status 1A
- **DAY 5** – he successfully underwent deceased donor LT
- Liver explant showed cholestatic hepatitis on chronic hepatitis with cirrhosis consistent with WD
- **DAY 19** – he was discharged with recovery of renal function

DISCUSSION

- NH₄ tetrathiomolybdate is an efficacious treatment option for neurologic predominant WD but not yet commercially available³.
- Zn monotherapy is as effective as penicillamine in preventing neurologic and hepatic decompensation by inhibiting Cu uptake by intestinal mucosa⁴.
- Current AASLD and EASL recommend monitoring liver function test, serum Cu, ceruloplasmin and physical exam twice yearly, and urine Cu yearly⁵.
- However, parameters for treatment failure of Zn need to be clearly defined to consider alternative treatment before disease progression occurs.
- LT is the only effective option for WD patients with decompensated liver disease unresponsive to medical therapy. One-year survival following LT ranges from 79-87%⁵.

CONCLUSION

- Despite being on treatment, liver failure can still occur suddenly in patients with WD

REFERENCE

1. Kathawala M, Hirschfield GM. Insights into the management of Wilson's disease. *Therap Adv Gastroenterol* 2017;10:889-905.
2. Rodriguez-Castro KI, Hevia-Urrutia FJ, Sturniolo GC. Wilson's disease: A review of what we have learned. *World J Hepatol* 2015;7:2859-70.
3. Lee VD, Northup PG, Berg CL. Resolution of decompensated cirrhosis from Wilson's disease with zinc monotherapy: a potential therapeutic option? *Clin Gastroenterol Hepatol* 2006;4:1069-71.
4. Saroli Palumbo C, Schilsky ML. Clinical practice guidelines in Wilson disease. *Ann Transl Med* 2019;7:S65.
5. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. *Hepatology* 2008;47:2089-111.